Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations
暂无分享,去创建一个
H. Brisse | H. Christiansen | A. Ferrari | C. Rodríguez-Galindo | M. Wygoda | D. Orbach | U. Kontny | L. Claude | G. Janssens | G. Österlundh | L. Gandola | M. Casanova | N. Jehanno | J. Zsiros | I. Brecht | B. Fresneau | G. Bisogno | D. Schneider | Y. Réguerre | A. Surun | T. Ben-Ami | T. Stachowicz-Stencel | A. Pourtsidis | M. Dragomir | R. Almaraz | Y. Reguerre | E. Bień | R. L. Almaraz
[1] A. Ferrari,et al. The European Paediatric Rare Tumours Network ‐ European Registry (PARTNER) project for very rare tumors in children , 2021, Pediatric blood & cancer.
[2] H. Amthauer,et al. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients , 2020, PloS one.
[3] M. Chua,et al. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.
[4] S. Revel-Vilk,et al. Nasopharyngeal carcinoma in children and young adults—Beyond 5‐year survival , 2020, Pediatric blood & cancer.
[5] M. Chua,et al. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation? , 2020, International journal of cancer.
[6] D. Kannarunimit,et al. Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with pretreatment plasma Epstein-Barr virus DNA level in a non-Chinese population: secondary analysis from a prospective randomized trial. , 2019, Japanese journal of clinical oncology.
[7] Y. Lu,et al. Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with 10-year follow-up. , 2019, Oral oncology.
[8] A. Pappo,et al. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Orbach,et al. Update in pediatric nasopharynx undifferentiated carcinoma. , 2019, The British journal of radiology.
[10] J. Noh,et al. Early clinical outcomes of helical tomotherapy/intensity‐modulated proton therapy combination in nasopharynx cancer , 2019, Cancer science.
[11] H. Mai,et al. Effect of local treatment for metastasis and its sequence with chemotherapy on prognosis of post-treatment metastatic nasopharyngeal carcinoma patients. , 2019, Oral oncology.
[12] D. Orbach,et al. Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience , 2019, Strahlentherapie und Onkologie.
[13] Brian O'Sullivan,et al. The addition of pretreatment plasma Epstein–Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification , 2019, International journal of cancer.
[14] Ying Sun,et al. Relationship between pretreatment concentration of plasma Epstein‐Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation , 2018, Cancer medicine.
[15] Ying Sun,et al. Proposed modifications and incorporation of plasma Epstein‐Barr virus DNA improve the TNM staging system for Epstein‐Barr virus‐related nasopharyngeal carcinoma , 2018, Cancer.
[16] K. Oktay,et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] N. Picard,et al. Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx , 2018 .
[18] V. Bišof,et al. Comparison of intensity modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) and a 3-dimensional conformal parotid gland-sparing radiotherapy (ConPas 3D-CRT) in treatment of nasopharyngeal carcinoma: a mono-institutional experience , 2018, La radiologia medica.
[19] San-Gang Wu,et al. Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: A population-based analysis. , 2017, Oral oncology.
[20] L. Liang,et al. Quantification of familial risk of nasopharyngeal carcinoma in a high‐incidence area , 2017, Cancer.
[21] L. Kong,et al. Use of Radiation Therapy in Metastatic Nasopharyngeal Cancer Improves Survival: A SEER Analysis , 2017, Scientific Reports.
[22] Xiang Guo,et al. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma , 2017, Journal of Cancer Research and Clinical Oncology.
[23] Yun-bin Chen,et al. Unidimensional measurement may be superior to assess primary tumor response after neoadjuvant chemotherapy for nasopharyngeal carcinoma , 2017, Oncotarget.
[24] C. Borg,et al. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach. , 2017, Seminars in oncology.
[25] Shi Qi,et al. 18F-FLT and 18F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results , 2017, Scientific Reports.
[26] F. Liu,et al. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma , 2017, Radiation oncology.
[27] Jianji Pan,et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial , 2016, The Lancet.
[28] V. Lee,et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma , 2016, Proceedings of the National Academy of Sciences.
[29] Y. Mao,et al. The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma , 2016, Scientific Reports.
[30] T. Jovanović,et al. Characterization of the Variability of Epstein-Barr Virus Genes in Nasopharyngeal Biopsies: Potential Predictors for Carcinoma Progression , 2016, PloS one.
[31] J. W. Lam,et al. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma. , 2016, Chinese clinical oncology.
[32] A. Garden,et al. Intensity‐modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes , 2016, Head & neck.
[33] P. Sham,et al. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma , 2016, Proceedings of the National Academy of Sciences.
[34] Jianji Pan,et al. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents , 2016, Cancer Chemotherapy and Pharmacology.
[35] Wei Zheng,et al. Multimodality Treatment May Improve the Survival Rate of Patients with Metastatic Nasopharyngeal Carcinoma with Good Performance Status , 2016, PloS one.
[36] Ying Sun,et al. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy , 2015, Oncotarget.
[37] H. Mai,et al. Plasma Epstein–Barr Viral Deoxyribonucleic Acid Predicts Worse Outcomes in Pediatric Nonmetastatic Nasopharyngeal Carcinoma Patients , 2015, Medicine.
[38] Ying Sun,et al. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. , 2015, International journal of radiation oncology, biology, physics.
[39] Jun Ma,et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. , 2015, European Journal of Cancer.
[40] Longzhen Zhang,et al. A Randomized Pilot Trial Comparing Position Emission Tomography (PET)-Guided Dose Escalation Radiotherapy to Conventional Radiotherapy in Chemoradiotherapy Treatment of Locally Advanced Nasopharyngeal Carcinoma , 2015, PloS one.
[41] W. Liang,et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma , 2015, Medical Oncology.
[42] T. Gupta,et al. PO-120: Clinical impact of metabolic and anatomic imaging in nasopharyngeal carcinoma treated with chemo-radiotherapy , 2015 .
[43] Christopher W. Dawson,et al. Epstein-Barr virus and nasopharyngeal carcinoma , 2014, Chinese journal of cancer.
[44] G. Shen,et al. Meta-analysis of diagnostic value of 18F-FDG PET or PET/CT for detecting lymph node and distant metastases in patients with nasopharyngeal carcinoma. , 2014, The British journal of radiology.
[45] M. Truong,et al. FDG PET/CT in the management of nasopharyngeal carcinoma. , 2014, AJR. American journal of roentgenology.
[46] Shuxing Li,et al. Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area , 2014, Oncology Research and Treatment.
[47] R. Sun,et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis , 2013, Chinese journal of cancer.
[48] M. Kohli,et al. Response criteria in oncologic imaging: review of traditional and new criteria. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.
[49] Y. Shih,et al. Long‐term survival analysis of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA levels , 2013, Cancer.
[50] Ji-An Liang,et al. Accuracy of whole-body FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma: a systematic review and meta-analysis. , 2013, European journal of radiology.
[51] X. An,et al. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma , 2013, Cancer Chemotherapy and Pharmacology.
[52] X. An,et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. , 2012, Oral oncology.
[53] H. Christiansen,et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults , 2012, Cancer.
[54] S. Zhang,et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[55] Wen-Qi Jiang,et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma , 2012, Journal of Cancer Research and Clinical Oncology.
[56] A. Ferrari,et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents , 2012, Cancer.
[57] Matthew J. Krasin,et al. PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[58] X. An,et al. Plasma Epstein‐Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy , 2011, Cancer.
[59] T. Yau,et al. A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma. , 2011, Oral oncology.
[60] E. Tan,et al. Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] A. King,et al. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. , 2011, Radiology.
[62] Hao Liu,et al. Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma , 2010, Journal of immunotherapy.
[63] M. Chua,et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma , 2009, Head & neck.
[64] Riccardo Calandrino,et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. , 2008, International journal of radiation oncology, biology, physics.
[65] F. Bray,et al. Age-Incidence Curves of Nasopharyngeal Carcinoma Worldwide: Bimodality in Low-Risk Populations and Aetiologic Implications , 2008, Cancer Epidemiology Biomarkers & Prevention.
[66] T. Mok,et al. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein–Barr virus DNA as a biomarker of efficacy , 2008, Cancer Chemotherapy and Pharmacology.
[67] J. Klijanienko,et al. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: Radiotherapy dose adaptation after chemotherapy response to minimize late effects , 2008, Pediatric blood & cancer.
[68] Uwe Oelfke,et al. Radiation Oncology Intensity-modulated Radiotherapy of Nasopharyngeal Carcinoma: a Comparative Treatment Planning Study of Photons and Protons , 2022 .
[69] T. Yen,et al. 18F-FDG PET Can Replace Conventional Work-up in Primary M Staging of Nonkeratinizing Nasopharyngeal Carcinoma , 2007, Journal of Nuclear Medicine.
[70] D. Yeung,et al. Nasopharyngeal cancers: which method should be used to measure these irregularly shaped tumors on cross-sectional imaging? , 2007, International journal of radiation oncology, biology, physics.
[71] Jin-Ching Lin,et al. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. , 2007, International journal of radiation oncology, biology, physics.
[72] H. Heslop,et al. A Single Institution Experience With Pediatric Nasopharyngeal Carcinoma: High Incidence of Toxicity Associated With Platinum-based Chemotherapy Plus IMRT , 2007, Journal of pediatric hematology/oncology.
[73] T. Yen,et al. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] Jang-Yang Chang,et al. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin‐resistant nasopharyngeal carcinoma , 2006, Head & neck.
[75] C. Hess,et al. Treatment of nasopharyngeal carcinoma in children and adolescents , 2005, Cancer.
[76] A. Kuten,et al. Pediatric nasopharyngeal carcinoma: Better prognosis and increased c‐Kit expression as compared to adults , 2005, Pediatric blood & cancer.
[77] B. Vicandi,et al. Fine‐needle aspiration cytology of metastatic nasopharyngeal carcinoma , 2005, Diagnostic cytopathology.
[78] G. Swanson,et al. Preradiation chemotherapy with methotrexate, cisplatin, 5‐fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma , 2005, Cancer.
[79] Y. Shugart,et al. Complex segregation analysis of nasopharyngeal carcinoma in Guangdong, China: evidence for a multifactorial mode of inheritance (complex segregation analysis of NPC in China) , 2005, European Journal of Human Genetics.
[80] Y. Cheung,et al. Phase II study of irinotecan (CPT‐11) as salvage therapy for advanced nasopharyngeal carcinoma , 2005, Cancer.
[81] A. Kuten,et al. Prevalence and relevance of EBV latency in nasopharyngeal carcinoma in Israel , 2004, Journal of Clinical Pathology.
[82] S. M. Kollur,et al. Fine‐needle aspiration cytology of metastatic nasopharyngeal carcinoma in cervical lymph nodes: Comparison with metastatic squamous‐cell carcinoma, and Hodgkin's and non‐Hodgkin's lymphoma , 2003, Diagnostic cytopathology.
[83] L. Peters,et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] D Machin,et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[85] A. Chan,et al. The use of brush cytology and directed biopsies for the detection of nasopharyngeal carcinoma and precursor lesions , 2001, Head & neck.
[86] C. Dykewicz. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[87] O. Uzel,et al. Nasopharyngeal carcinoma in childhood: long-term results of 32 patients. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[88] A. King,et al. Paranasopharyngeal space involvement in nasopharyngeal cancer: detection by CT and MRI. , 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).
[89] D. Chua,et al. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. , 2000, European journal of cancer.
[90] M. Serin,et al. Nasopharyngeal carcinoma in childhood and adolescence. , 1998, Medical and pediatric oncology.
[91] Kathryn Flynn,et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. , 1995, The New England journal of medicine.
[92] M. Chan,et al. Fine needle aspiration cytodiagnosis of nasopharyngeal carcinoma in cervical lymph nodes. A study of 40 cases. , 1989, Acta cytologica.
[93] M. Loriot,et al. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]. , 2018, Bulletin du cancer.
[94] D. Orbach,et al. Childhood Nasopharyngeal Carcinoma: State-of-the-Art, and Questions for the Future , 2018, Journal of pediatric hematology/oncology.
[95] Shu-xu Zhang,et al. Comparison of SPECT/CT, MRI and CT in diagnosis of skull base bone invasion in nasopharyngeal carcinoma. , 2014, Bio-medical materials and engineering.
[96] R. Ribeiro,et al. Prognostic factors and long‐term outcomes of childhood nasopharyngeal carcinoma , 2011, Cancer.
[97] T. Ciuleanu,et al. Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study. , 2008, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[98] Jin-Ching Lin,et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. , 2007, International journal of radiation oncology, biology, physics.
[99] Sarbani Ghosh,et al. Nasopharyngeal carcinoma in children: ten years' experience at the Tata Memorial Hospital, Mumbai. , 2004, International journal of radiation oncology, biology, physics.
[100] N. Al-Rajhi,et al. Nasopharyngeal Carcinoma in Children and Adolescents , 2000 .
[101] K. Shanmugaratnam. Histological typing of nasopharyngeal carcinoma. , 1978, IARC scientific publications.